Longwood Healthcare Leaders
San Francisco CEO
January 6 - 7, 2024
Longwood Healthcare Leaders San Francisco CEO brings together leading biopharma CEOs, heads of R&D, top academic researchers, and life science investors the weekend prior to the JP Morgan Healthcare Conference for off-the-record discussion, co-hosted by former Stanford President Marc Tessier-Lavigne and held at the Four Seasons San Francisco. Join us for an intimate event with leaders in the industry.
Featured Speakers
Academia, Regulatory & Provider
BioPharma CEOs
R&D & Therapeutic Area Leaders
BD & Strategy
Longwood Portfolio
Agenda
Saturday, January 6, 2024
7:00 am
REGISTRATION & NETWORKING BREAKFAST
7:30 am
LONGWOOD FUND INTRODUCTION
Christoph Westphal, General Partner, Longwood Fund
8:00 am
BIG BIOPHARMA PIPELINE SOURCING
Joachim Fruebis, Corporate VP, Head, Cell Therapy R&D, Novo Nordisk
Shiva Malek, Global Head, Oncology, Novartis
Iskra Reic, EVP, Vaccines & Immune Therapies, AstraZeneca
Moderator: Cody Powers, Principal, ZS Associates
8:30 am
CROSS-BORDER COLLABORATION
Ed Hu, Vice Chair & Global CIO, WuXi
Richard Paulson, CEO, Karyopharm
Nikolay Savchuk, Chair, Viriom Inc
Bill Watt, President, Astellas Venture Management
Moderator: James Sapirstein, CEO, First Wave BioPharma
9:00 am
FIRESIDE CHAT: SPOTLIGHT ON STANFORD INNOVATION
Lloyd Minor, Dean, Stanford School of Medicine
Sylvia Plevritis, Chair, Department of Biomedical Data Science, Stanford University
Marc Tessier-Lavigne, former President, Stanford University
Irv Weissman, Ludwig Professor, Clinical Investigation in Cancer Research, Stanford University
Moderator: Christoph Westphal, General Partner, Longwood Fund
9:25 am
ENSURING HEALTH EQUITY AND ACCESS
Aida Habtezion, CMO, Head, WW Medical & Safety, Pfizer
Steve Hahn, CEO, Harbinger Health; former Commissioner, FDA
Sabrina Johnson, CEO, Daré Bioscience
Cindy Perettie, EVP, Kite, a Gilead Company
Moderator: Ariel Katz, CEO, H1
9:55 am
NETWORKING BREAK
10:20 am
R&D COLLABORATION
Nenad Grmusa, CEO, DEM BioPharma
Sek Kathiresan, CEO, Verve Therapeutics
Johan Luthman, EVP, R&D, Lundbeck
Ryan Richardson¸ Chief Strategy Officer, BioNTech
Moderator: Zhen Su, CEO, Marengo Therapeutics
10:50 am
ACCELERATING DRUG DEVELOPMENT
Judy Chou, CEO, AltruBio
Fabrice Chouraqui, CEO, Cellarity
Larry Hamann, CEO, Interdict Bio
Carl Hansen, CEO, Abcellera
Moderator: Jim Anthony, President, Parexel Biotech
11:20 am
RECRUITING AND RETAINING TALENT
Ram Aiyar¸ CEO, Korro Bio
Quita Highsmith, Chief Diversity Officer, Genentech
Catherine Sohn, Board Director, Jazz Pharmaceuticals
Alex Zhavoronkov, CEO, Insilco Medicine
Moderator: Sandra Glucksmann, CEO, Sensorium Therapeutics
11:50 am
FIRESIDE CHAT: FROM PHARMA TO BIOTECH CEO
Marianne De Backer, CEO, Vir Biotechnology
Henry Gosebruch, CEO, Neumora
Mathai Mammen, CEO, FogPharma
Moderator: John Flavin, CEO, Portal Innovations
12:10 pm
NETWORKING LUNCHEON
1:00 pm
RARE DISEASE INNOVATION
Nasha Fitter, CEO, FOXG1 Research
Ioannis Sapountzis, Corporate SVP & Global Head, Therapeutic Areas, Boehringer Ingelheim
Shalini Sharp, former CFO, Ultragenyx
Jason Yaffe, Assoc Partner, Global Rare Disease Lead, ZS
Moderator: Brinda Balakrishnan, CBDO, Biomarin
1:30 pm
GETTING TO REGULATORY APPROVAL
Sandi Dunn, CEO, Phoenix Molecular Designs
Marshall Fordyce, CEO, Vera Therapeutics
Orr Inbar, CEO, QuantHealth
Thomas Lonngren, Chair, Egetis; former Executive Director, EMA
Moderator: Pascal Touchon, CEO, Atara
2:00 pm
DEAL-MAKING LANDSCAPE
Philippe Lopes-Fernandes, CBO, Ipsen
George Magrath, CEO, Ocuphire Pharma
George Montgomery, CFO, Neuvogen
Dan Paterson, CEO, Verastem Oncology
Moderator: Mark McKenna, former CEO, Prometheus Biosciences
2:30 pm
INNOVATIVE COMMERCIAL MODELS
Chris Benecchi, CBO, Sage Therapeutics
Teresa Bitetti, President, Global Oncology, Takeda
Arpa Garay, former CCO, Moderna
Kabir Nath, CEO, COMPASS Pathways
Moderator: Stephen Blaising, Co-Founder & Chair, Brain Surgery Worldwide, Inc.
3:00 pm
NETWORKING BREAK
3:30 pm
REGULATORY & INDUSTRY ROUNDTABLE
Peter Marks, Director, CBER, FDA
Moderator: Christoph Westphal, General Partner, Longwood Fund
4:00 pm
THE FUTURE OF GENETIC THERAPIES
Michael Amoroso, CEO, Precision BioSciences
Jason Cole, CEO, SalioGen
Gilmore O’Neill, CEO, Editas Medicine
Morten Sogaard, President, Astellas GT Research & Tech Ops, Astellas
Moderator: Alex Harding, Head, BD, CRISPR Therapeutics
4:30 pm
STRENGTH IN THE SYNDICATE
Vik Bajaj, Managing Director, Foresite Capital
Alaa Halawa, Executive Director, Mubadala
Ittai Harel, Managing Partner, Healthtech, Pitango
Rachel Mears, Partner, Jeito Capital
Moderator: Aleks Radovic-Moreno, Partner, Longwood Fund
5:00 – 7:00 pm
COCKTAIL RECEPTION
Sunday, January 7, 2024
7:00 am
REGISTRATION & NETWORKING BREAKFAST
7:30 am
LONGWOOD FUND INTRODUCTION
David Steinberg, General Partner, Longwood Fund
8:00 am
R&D TRANSFORMATION
Julie Gerberding, CEO, Foundation for the NIH
Anirvan Ghosh, CEO, Unity Biotechnology
Reshma Rangwala, CMO, Karyopharm
Liz Thompson, EVP, R&D, Rare Disease, Amgen
Moderator: Yiannis Kiachopoulos, CEO, Causaly
8:30 am
INNOVATION IN CLINICAL TRIAL DESIGN
John Glasspool, CEO, Anthos Therapeutics
Ed Kaye, CEO, Stoke Therapeutics
Lisa Ricciardi, CEO, Cognition Therapeutics
Jim Wooldridge, CMO, Immunitas
Moderator: Murray Aitken, Executive Director, IQVIA Institute
9:00 am
PLATFORM TO PRODUCT PLAY
Ken Drazan, CEO, ArsenalBio
Margo Georgiadis, CEO, Montai Health
Mark Kotter, CEO, bit.bio
Neil Weir, CEO, Sitryx
Moderator: Kara Carter, EIR, Evotec
9:30 am
FIRESIDE CHAT
Jane Grogan, EVP, Head, Research, Biogen
Frank Nestle, Global Head, Research & CSO, Sanofi
Moderator: David Steinberg, General Partner, Longwood Fund
9:50 am
NETWORKING BREAK
10:20 am
BIG BIOPHARMA R&D
Sharon Barr, EVP, BioPharmaceuticals R&D, AstraZeneca
Ajay Nirula, SVP, Immunology, Eli Lilly & Co
Dominik Ruettinger, SVP, Global Head Research & Early Development Oncology, Bayer Pharma
Moderator: Carolyn Magill, CEO, Aetion
10:50 am
MAINTAINING FOCUS ON THE PATIENT
Anne Klibanski, President & CEO, Mass General Brigham
David Loew, CEO, Ipsen
Paul Markovich, CEO, Blue Shield California
Moderator: DA Gros, CEO, Eledon
11:20 am
EVOLVING PARTNERING STRATEGY
Nadim Ahmed, CEO, Cullinan Oncology
Francisco Leon, CEO, Tolerance Bio
Matthias Muellenbeck, SVP, Head Global BD & Alliance Management, EMD Serono
Jeff Rona, CBFO, Ovid Therapeutics
Moderator: Anat Naschitz, CEO, 9xc
11:50 am
MANAGING THE RUNWAY
Al Beardsley, COO, Galera Therapeutics
Natalia Misciatteli, CEO, AAVantgarde Bio
Stefan Scherer, CEO, 3T Biosciences
Amanda Wagner, CEO, Immunitas
Moderator: Axel Hoos, former CEO, Scorpion Therapeutics
12:20 pm
NETWORKING LUNCHEON
1:00 pm
POLICY IMPACT ON INNOVATON
Wendy Bartie, SVP, GM US Hematology & Cell Therapy, Bristol Myers Squibb
Alan Eisenberg, former Head, Global Public Policy & Government Relations, Alnylam
Nouhad Husseini, SVP, Head, BD & Corporate Strategy, Regeneron
Aradhana Sarin, CFO, AstraZeneca
Moderator: Luba Greenwood, CEO, Kojin Therapeutics
1:30 pm
ADVANCING RESEARCH INTO THE CLINIC
Stewart Campbell, CEO, Axial Therapeutics
Susan Hill, CEO, Mestag
Marco Quarta, CEO, Rubedo Life Sciences
Sunil Verma, SVP, Global Head of Oncology, Medical, AstraZeneca
Moderator: Robert LaCaze, CEO, Mnemo Therapeutics
2:00 pm
FIRESIDE CHAT
Robert Plenge, EVP, Chief Research Officer, Head, Research, BMS
Tim Walbert, CEO, Horizon Therapeutics
Anne Wojcicki, CEO, 23andMe
George Yancopoulos, President & CSO, Regeneron
Moderator: Christoph Westphal, General Partner, Longwood Fund
2:25 pm
NETWORKING BREAK
2:50 pm
THE NEXT WAVE OF TARGETED THERAPIES
Janice Chen, CTO, Mammoth Biosciences
Jay Kim, CEO, K2B Therapeutics
Gaurav Shah, CEO, Rocket Pharma
Phil Vickers, CEO, Solu Therapeutics
Moderator: Bruce Sunstein, Partner, Sunstein LLP
3:20 pm
EXTERNAL INNOVATION
Keith Gottesdiener, CEO, Prime Medicine
Rosana Kapeller, CEO, Rome Therapeutics
Jim Reddoch, EVP, Investments & CSO, Royalty Pharma
Catherine Sabatos-Peyton, CEO, Larkspur Biosciences
Moderator: Jeb Keiper, CEO, Nimbus Therapeutics
3:50 pm
INVESTMENT OUTLOOK
Mike Ehlers, CSO & Venture Partner, Apple Tree Partners
Ansbert Gadicke, Managing Partner, MPM BioImpact
Ursheet Parikh, Partner, Mayfield
Kiran Reddy, Senior Managing Director, Blackstone Life Sciences
Moderator: David Steinberg, General Partner, Longwood Fund
Speaking Faculty